Tkaczyk Marcin, Czupryniak Aneta, Lukamowicz Jolanta, Ksiazek Edyta, Półtorak-Krawczyk Anna, Swiatkowska Ewa, Nowicki Michał
Klinika Nefrologii i Dializoterapii, Instytutu Centrum Zdrowia Matki Polki, Lódź.
Przegl Lek. 2006;63 Suppl 3:217-9.
Glucose intolerance which is frequently found in patients with the idiopathic nephrotic syndrome (INS) may be linked to an increased cardiovascular risk in these patients. Recently it has been suggested that proteinuria and steroid treatment may independently affect insulin sensitivity. The aim of the study was to assess insulin resistance (IR) and beta-cell function in children with INS at various stages of the disease. The study group comprised 66 children (32 male, 34 female; age 8.1 +/- 5.0 years). 20 healthy, sex- and age-matched subjects served as controls. The study group was divided into 3 subgroups: A (n=24) children in relapse of INS (steroids 60 mg/m2/48h; proteinuria 1.02 +/- 1.04 g/dl); B (n=20) in remission treated with steroids (30 mg/ m2/48h); C (n=22) in remission but without steroids. Fasting glucose and insulin levels were measured to calculate insulin resistance (HOMA-IR) and beta-cell function (HOMA-beta) using Homeostatic Model Assessment. Fasting glucose was within normal range in all subjects. HOMA-IR was significantly higher in group A (3.2 +/- 3.3) and group B (2.4 +/- 1.7) than in group C (1.45 +/- 1.6 and controls (1.12 +/- 0.6) (p<0.05). HOMA-beta was significantly higher in group A and B than in C and controls (p<0.05). In multivariate analysis HOMA-IR correlated with proteinuria (beta=0.45, p<0.001), steroid dose (beta=0.32) and BMI (beta=0.42). In conclusion, an increase in insulin resistance with compensatory enhanced beta-cell secretion is a typical finding in children with INS treated with steroids. Proteinuria seems to be an independent risk factor for decreased insulin sensitivity.
特发性肾病综合征(INS)患者中常见的葡萄糖耐量异常可能与这些患者心血管风险增加有关。最近有人提出,蛋白尿和类固醇治疗可能独立影响胰岛素敏感性。本研究的目的是评估处于疾病不同阶段的INS患儿的胰岛素抵抗(IR)和β细胞功能。研究组包括66名儿童(32名男性,34名女性;年龄8.1±5.0岁)。20名健康的、年龄和性别匹配的受试者作为对照。研究组分为3个亚组:A组(n = 24)为INS复发患儿(类固醇60 mg/m²/48小时;蛋白尿1.02±1.04 g/dl);B组(n = 20)为接受类固醇治疗(30 mg/m²/48小时)的缓解期患儿;C组(n = 22)为缓解期但未使用类固醇的患儿。测量空腹血糖和胰岛素水平,使用稳态模型评估来计算胰岛素抵抗(HOMA-IR)和β细胞功能(HOMA-β)。所有受试者的空腹血糖均在正常范围内。A组(3.2±3.3)和B组(2.4±1.7)的HOMA-IR显著高于C组(1.45±1.6)和对照组(1.12±0.6)(p<0.05)。A组和B组的HOMA-β显著高于C组和对照组(p<0.05)。多变量分析显示,HOMA-IR与蛋白尿(β = 0.45,p<0.001)、类固醇剂量(β = 0.32)和BMI(β = 0.42)相关。总之,在用类固醇治疗的INS患儿中,胰岛素抵抗增加并伴有代偿性β细胞分泌增强是典型表现。蛋白尿似乎是胰岛素敏感性降低的独立危险因素。